4 blood markers may predict outcomes in pulmonary sarcoidosis
When combined, four newly found blood biomarkers nearly perfectly predicted disease progression in pulmonary sarcoidosis patients in a study.| Sarcoidosis News
EFZO-FIT, a Phase 3 clinical study testing efzofitimod for pulmonary sarcoidosis, failed to meet its main goal of significantly reducing the need for corticosteroids among people with the rare inflammatory disease. […] The post Efzofitimod misses main goal in large pulmonary sarcoidosis trial appeared first on Sarcoidosis News.| Sarcoidosis News – The Web's Daily Resource for Sarcoidosis News
When combined, four newly found blood biomarkers nearly perfectly predicted disease progression in pulmonary sarcoidosis patients in a study.| Sarcoidosis News
The safety and tolerability is being tested of two XTMAB-16 doses against a placebo in patients on a stable corticosteroid dose.| Sarcoidosis News
